GSK's vaccine against respiratory syncytial virus (RSV) is one of the top prospects in its pipeline, but also one with considerable competition, so needs strong data to support the programme.

LONDON, - British drugmaker GSK will no longer set diversity targets, it said on Thursday, as it became the latest company to scale back or abandon such goals in response to the U.S. president's ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other best vaccine stocks to buy now. On February 24, CNBC reported that President Trump declared that ...

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of GSK plc (NYSE: GSK). Shareholders who purchased shares of GSK during the class period ...

In April 2016, we entered into a platform technology transfer and license agreement with GSK to research, develop and commercialize up to six bispecific antibodies generated using our Azymetric™ ...

GSK plans to file for approval of Jemperli in this setting in the first half of 2023, and if it gets the nod from regulators the drug could claim a category of the endometrial cancer market ...

Pharmaceutical giant GSK has officially sealed its acquisition of biopharma company IDRx Inc. in a high-stakes $1.15 billion deal aimed at strengthening its foothold in gastrointestinal cancer ...

NEW YORK, NY / ACCESS Newswire / February 22, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws ...

Liverpool visit the Etihad Stadium on Sunday under a little pressure to pick up three points. The Reds have not beaten Man City away from home in the Premier League since 2015, but could really do ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. UK drugmaker GSK is struggling to convince the market that it can deliver on its plans to refill its ...

Get Our Latest Report on GSK GSK Stock Down 0.9 % Shares of GSK stock opened at $36.62 on Friday. The firm’s 50 day moving average price is $34.61 and its 200-day moving average price is $37.36 ...

GSK Plc is a long-term underperformer among Europe’s Big Pharma stocks. And with key drug patents set to expire and vaccine sales falling, some market participants say it may draw in activist ...